Safety test of C5a inhibitory peptide

Safety test of C5a anaphylatoxin inhibitory peptide, AcPepA - INHIBITOR OF ANAPHYLATOXIN

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1091220027

Enrollment

Registered

2009-04-06

Start date

2009-08-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic inflammatory response syndrome

Interventions

Intervention type:DRUG Name of intervention:AcPepA,Safety test of AcPepA Dose form / Japanese Medical Device Nomenclature:INJECTION,INJECTION Route of administration / Site of application:INTRAVENOUS

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Over 45 years of age to exclude reproductive ages.

Exclusion criteria

Exclusion criteria: Chronic infectious disease patients

Design outcomes

Primary

Measure	Time frame
ECG, Blood pressure, heart rate, respiratory rate, body temperature, kidney function test, liver function test, blood cell profile, breast X ray	—

Countries

Japan

Contacts

Public ContactHidechika Okada, MD, PhD.

Fukushimura Hospital

hideokada@chojuken.net+81-532-46-8930

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026